Literature DB >> 22473094

Kidney cancer: High-dose intermittent sunitinib therapy retains the crown.

Iley Ozerlat.   

Abstract

Entities:  

Year:  2012        PMID： 22473094     DOI： 10.1038/nrclinonc.2012.55

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Mark R Olsen; Gary R Hudes; John M Burke; William J Edenfield; George Wilding; Neeraj Agarwal; John A Thompson; David Cella; Akintunde Bello; Beata Korytowsky; Jinyu Yuan; Olga Valota; Bridget Martell; Subramanian Hariharan; Robert A Figlin
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.